Ontamalimab

Summary

Ontamalimab (CHEMBL2109511) is a phase-3 clinical-stage antibody; indicated across 2 conditions including crohn disease and ulcerative colitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109511
Name	Ontamalimab
Type	Antibody
Max phase	3

Also known as: Ontamalimab, PF-00547659, SHP-647, Shp647, SHP647, ONTAMALIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Crohn disease	3	MONDO:0005011	EFO:0000384
ulcerative colitis	3	MONDO:0005101	EFO:0000729

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE3	7
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03259308	PHASE3	TERMINATED	Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
NCT03259334	PHASE3	TERMINATED	Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
NCT03283085	PHASE3	COMPLETED	A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn’s Disease (AIDA)
NCT03290781	PHASE3	COMPLETED	An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis
NCT03559517	PHASE3	TERMINATED	Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn’s Disease (CARMEN CD 305)
NCT03566823	PHASE3	TERMINATED	Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn’s Disease (CARMEN CD 306)
NCT03627091	PHASE3	TERMINATED	Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn’s Disease (CARMEN CD 307)
NCT01298492	PHASE2	COMPLETED	A Study To Monitor Long-Term Treatment With PF-00547659
NCT01771809	PHASE2	COMPLETED	Long-Term Safety Of PF-00547659 In Ulcerative Colitis
NCT07052682	PHASE1	TERMINATED	A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).